B-cell receptor recognizing HIV-1 envelope (HIV-1 Env-specific BCR)

B-cell receptors (BCRs) recognizing the HIV-1 envelope (Env) glycoprotein are the primary targets for modern structure-based vaccine design aimed at preventing HIV-1 infection (Jardine et al., Science, 2013). These receptors are membrane-bound immunoglobulins on the surface of B cells that recognize the Env trimer, the only viral protein exposed on the surface of HIV-1 virions (Haynes et al., Nature Biotechnology, 2023). Because the virus employs extensive glycan shielding and high mutational variability, most BCRs that bind Env do not produce neutralizing antibodies. Consequently, therapeutic strategies like germline targeting use engineered immunogens, such as eOD-GT8 60mer, to specifically engage rare naive BCRs that possess the genetic potential to evolve into broadly neutralizing antibodies (bNAbs) (Leggat et al., Science, 2022). Upon binding, these BCRs trigger B-cell activation and initiate a complex process of somatic hypermutation and affinity maturation within germinal centers (Stamatatos et al., Science, 2021). This targeted approach is designed to overcome the immunological barriers that typically prevent the development of protective immunity during natural infection. Monitoring the frequency and sequence evolution of these specific BCRs serves as a critical biomarker for vaccine efficacy in clinical trials (Cohen, Science, 2021).

Other names

HIV-1 envelope-specific B-cell receptorEnv-specific BCRHIV-1 Env-binding B-cell receptorEnv-reactive BCR

Germline-targeting immunogens bind to and activate specific naive B-cell receptors to initiate the affinity maturation process required to generate broadly neutralizing antibodies (bNAbs).